Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Coinfection of humans with Hepatitis B Virus (HBV) and non-viral pathogens may worsen the outcome of HBV infection on the liver. This study determined the prevalence of Heliobacter pylori, Salmonella typhi, Plasmodium falciparum, and Toxoplasma gondii among Hepatitis B Virus (HBV)-infected persons in the Greater Accra Region (GAR) of Ghana and examined how such co-infections might affect the levels of selected liver function markers (LFM). The design was cross-sectional, involving 120 HBsAg-positive HBV-infected persons. Blood samples were collected. H. pylori, S. typhi, P. falciparum, and T. gondii were screened for, from the blood using lateral flow immunochromatographic assays. P. falciparum infection was further confirmed by blood film microscopy. LFM's and blood platelets were measured using clinical chemistry and reflective light suppression/silicon photomultiplier techniques respectively. Data were analyzed using SPSS v. 23.0, and GraphPad 7.0. Seventy-five,75(62.5%) of the participants were males, and 51.7% were 21-to-30-years old. Prevalence of H. pylori, S. typhi, T.gondii and P. falciparum were 40.8% (95% CI: 32.5-49.8), 2.5% (95% CI: 0.8-7.1), 19.2% (95% CI: 13.1-27.1), and 2.5% (95% CI: 0.8-7.1) respectively. Levels of Alanine transaminase (ALT) were higher in HBV-H.pylori coinfected persons compared with HBV-only (33.5vs23.5IU,p < 0.001). HBV-infected persons in the GAR have high prevalences of H. pylori and T. gondii coinfections. Some LFM's were elevated due to such coinfections. Care givers would need to widen their screening, monitoring, and diagnosis of HBV coinfections, beyond examination for malaria parasites, and monitor other possible causes of biochemical derangements among HBV-infected persons.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412962PMC
http://dx.doi.org/10.1371/journal.pgph.0005132DOI Listing

Publication Analysis

Top Keywords

hepatitis virus
12
pylori salmonella
8
salmonella typhi
8
typhi plasmodium
8
plasmodium falciparum
8
falciparum toxoplasma
8
toxoplasma gondii
8
liver function
8
function markers
8
greater accra
8

Similar Publications

Repurposing disulfiram: An innovative inhibitory approach against a broad spectrum of viruses.

Biochem Biophys Res Commun

September 2025

Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China; Department of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandon

Disulfiram (DSF), an FDA-approved therapeutic agent for alcohol dependence, has recently attracted considerable interest due to its broad-spectrum inhibitory effects against various viruses. Increasing evidence suggests that DSF can inhibit viral replication through two major mechanisms: the inhibition of viral protein catalytic activity and the ejection of Zn from viral proteins. This review comprehensively summarized the molecular mechanisms underlying DSF's antiviral activity against viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV), influenza virus, human immunodeficiency virus (HIV), and Kaposi sarcoma-associated herpes virus (KSHV), with a particular focus on its dual targeting of Cys residues and Zn coordination sites.

View Article and Find Full Text PDF

Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.

View Article and Find Full Text PDF

Background And Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14-25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17-35 kg.

View Article and Find Full Text PDF

Background: Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas.

Aim: To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver cancer.

Methods: Patients with current or past HBV infection receiving systemic treatments for liver cancer from March 2015 to March 2023 were identified using a territory-wide electronic database in Hong Kong.

View Article and Find Full Text PDF

Coinfection of humans with Hepatitis B Virus (HBV) and non-viral pathogens may worsen the outcome of HBV infection on the liver. This study determined the prevalence of Heliobacter pylori, Salmonella typhi, Plasmodium falciparum, and Toxoplasma gondii among Hepatitis B Virus (HBV)-infected persons in the Greater Accra Region (GAR) of Ghana and examined how such co-infections might affect the levels of selected liver function markers (LFM). The design was cross-sectional, involving 120 HBsAg-positive HBV-infected persons.

View Article and Find Full Text PDF